About Cumberland | Important Safety Information | Full Prescribing Information | News

Increased serum sodium maintained

The effect of VAPRISOL on serum sodium was demonstrated in an open-label study of 251 patients with euvolemic or hypervolemic hyponatremia, the primary endpoint of which was baseline adjusted serum sodium AUC over duration of treatment (mEq·hr/L). Patients were treated for 4 days with VAPRISOL 20 mg/day IV or 40 mg/day IV (n=37, n=214, respectively) following a 20-mg loading dose via 30-minute IV infusion. The mean baseline serum sodium concentrations in patients treated with VAPRISOL 20 mg/day IV or 40 mg/day IV were 122.5 mEq/L and 123.8 mEq/L, respectively.1,2

Increase in Mean Serum Sodium Concentration from Baseline to 30 Days Post-Treatment

  • Mean changes in serum sodium concentration from baseline to end of treatment (day 4) in patients receiving VAPRISOL 20 mg/day or 40 mg/day IV were 9.4 mEq/L and 8.8 mEq/L, respectively1
  • Increased serum sodium concentration was maintained for up to 30 days post-treatment1*

*The effect of VAPRISOL on maintenance of serum sodium concentration is not known.

REFERENCES: 1. Vaprisol® [Package Insert] Cumberland Pharmaceuticals Inc. Nashville, TN 2016 2. Palmer B, Rock A, Woodward, E Dose comparison of conivaptan (Vaprisol®) in patients with euvolem or hypervolemic hyponatremia -efficacy, safety, and pharmacokinetics. Drug Des Devel Ther. 2016; 10:339-351

Indication: VAPRISOL is indicated to raise serum sodium in hospitalized patients with euvolemic and hypervolemic hyponatremia.
Important Limitations: VAPRISOL has not been shown to be effective for the treatment of the signs and symptoms of heart failure and is not approved for this indication. It has not been established that raising serum sodium with VAPRISOL provides a symptomatic benefit to patients.


VAPRISOL is contraindicated in patients with hypovolemic hyponatremia. The coadministration of VAPRISOL with potent CYP3A inhibitors, such as ketoconazole, itraconazole, clarithromycin, ritonavir, and indinavir, is contraindicated. In addition, no benefit can be expected in patients unable to make urine.

Hyponatremia associated with heart failure: Safety data on the use of VAPRISOL in these patients are limited. Consider other treatment options.
Overly rapid correction of serum sodium: Monitor serum sodium, volume and neurologic status and if the patient develops an undesirably rapid rate of rise of serum, VAPRISOL should be discontinued. If serum sodium concentration continues to rise, VAPRISOL should not be resumed. Serious neurologic sequelae, including osmotic demyelination syndrome, can result from over rapid correction of serum sodium. In susceptible patients, including those with severe malnutrition, alcoholism or advanced liver disease, slower rates of correction should be used.
Hypovolemia or Hypotension: For patients who develop hypovolemia or hypotension while receiving VAPRISOL, VAPRISOL should be discontinued, and volume status and vital signs should be monitored.
Infusion site reactions: Serious reactions have occurred. Administer through large veins and change infusion site every 24 hours.

The most common adverse reactions (incidence ≥10%) reported in clinical trials were infusion site reactions (including phlebitis), pyrexia, hypokalemia, headache and orthostatic hypotension.

Potent CYP3A inhibitors may increase the exposure of conivaptan and are contraindicated. Generally avoid CYP3A substrates. Exposure to coadministered digoxin may be increased and digoxin levels should be monitored.

Use in Patients with Hepatic Impairment
In patients with moderate to severe hepatic impairment, initiate VAPRISOL with a loading dose of 10 mg over 30 minutes followed by 10 mg/day as a continuous infusion for 2 to 4 days. If no rise in serum sodium, VAPRISOL may be titrated upward to 20 mg/day.